Adicet Bio Inc. (ACET)
0.62
0.02 (3.09%)
At close: Apr 23, 2025, 3:59 PM
Company Description
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases.
The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients.
Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma.
The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors.
Adicet Bio, Inc. is based in Boston, Massachusetts.
Adicet Bio Inc.

Country | United States |
IPO Date | Jan 26, 2018 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 152 |
CEO | Dr. Aya Jakobovits Ph.D. |
Contact Details
Address: 200 Clarendon Street Boston, Massachusetts United States | |
Website | https://www.adicetbio.com |
Stock Details
Ticker Symbol | ACET |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001720580 |
CUSIP Number | 007002108 |
ISIN Number | US0070021086 |
Employer ID | 81-3305277 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Brian Nicholas Harvey | Chief Financial Officer |
Dr. Donald Healey Ph.D. | Chief Technology Officer |
Amy Locke | Chief Human Resource Officer |
Dr. Aya Jakobovits Ph.D. | Founder & Independent Director |
Dr. Blake Aftab Ph.D. | Senior Vice President & Chief Scientific Officer |
Dr. Julie Maltzman M.D. | Chief Medical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 21, 2025 | 4 | Filing |
Apr 21, 2025 | 3 | Filing |
Apr 17, 2025 | 8-K | Current Report |
Apr 11, 2025 | 8-K | Current Report |
Mar 26, 2025 | S-8 POS | Filing |
Mar 18, 2025 | 424B5 | Filing |
Mar 06, 2025 | S-8 | Filing |
Mar 06, 2025 | S-3 | Filing |
Mar 06, 2025 | 10-K | Annual Report |
Mar 06, 2025 | 8-K | Current Report |